These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2423804)

  • 21. Cardiovascular effects of indoramin in man--a dose ranging study.
    Nicholls DP; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1983 Jan; 15(1):31-6. PubMed ID: 6849741
    [No Abstract]   [Full Text] [Related]  

  • 22. A comparison of the effects of indoramin and yohimbine at pre- and postsynaptic alpha adrenoceptors of the rabbit pulmonary artery.
    Rhodes KF; Stannard M; Waterfall JF
    Biochem Pharmacol; 1983 Dec; 32(24):3875-7. PubMed ID: 6318775
    [No Abstract]   [Full Text] [Related]  

  • 23. Alpha-adrenergic blockade in the treatment of essential hypertension.
    De Leeuw PW; Birkenhäger WH
    Neth J Med; 1983; 26(9):274-82. PubMed ID: 6140644
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of indoramin added to oxprenolol and bendrofluazide as a third agent in severe hypertension.
    Marshall AJ; Kettle MA; Barritt DW
    Br J Clin Pharmacol; 1980 Sep; 10(3):217-21. PubMed ID: 7437237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cardiovascular effects of centrally and peripherally administered indoramin in conscious rats.
    Porter JP; Bonham AC; Mangiapane ML; Webb RL; Brody MJ
    Eur J Pharmacol; 1985 Feb; 109(1):9-17. PubMed ID: 3996469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute hemodynamic and hormonal response to indoramin in congestive heart failure.
    Olivari MT; Garberg VR; Selby T; Cohn JN; Levine TB
    Clin Pharmacol Ther; 1984 Sep; 36(3):297-301. PubMed ID: 6380878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.
    Nicholls DP; McNeill J; O'Connor PC; Harron DW; Leahey WJ; Shanks RG
    Br J Clin Pharmacol; 1984 Aug; 18(2):215-21. PubMed ID: 6386022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human pharmacology of indoramin.
    Coltart DJ; Lockhart JD; Royds RB; Turner P
    Br J Pharmacol; 1971 Oct; 43(2):467P-468P. PubMed ID: 4400576
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiovascular effects of intravenous indoramin hydrochloride in man.
    Coleman AJ; Leary WP; Asmal AC
    J Int Med Res; 1979; 7(6):511-8. PubMed ID: 520654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-adrenergic vasoconstriction and receptor subtypes in large coronary arteries of calves.
    Young MA; Vatner DE; Knight DR; Graham RM; Homcy CJ; Vatner SF
    Am J Physiol; 1988 Dec; 255(6 Pt 2):H1452-9. PubMed ID: 2904772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional study of the excitatory alpha-adrenoceptor in guinea pig ileum, in relation to the hypothesis of an atypical receptor.
    Bricola A; Jurkiewicz NH; Jurkiewicz A
    Ann N Y Acad Sci; 1997 May; 812():189-92. PubMed ID: 9186739
    [No Abstract]   [Full Text] [Related]  

  • 32. [Comparison of the effects of prazosin and phenoxybenzamine on arterial pressure, heart rate and plasma catecolamines in essential arterial hypertension].
    Mulvihill-Wilson J; Graham RM; Pettinger WA; Muckleroy C; Anderson S; Gaffney F; Blomqvist CG
    Cardiology; 1980; 66 Suppl 2():85-93. PubMed ID: 6116543
    [No Abstract]   [Full Text] [Related]  

  • 33. A trial of an alpha-adrenoreceptor blocking drug (indoramin) in exercise-induced bronchoconstriction.
    Seale JP; Anderson SD; Lindsay DA
    Scand J Respir Dis; 1976; 57(6):261-6. PubMed ID: 189384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double blind comparison of indoramin with clonidine in the treatment of moderate to severe essential hypertension.
    Yajnik BH; Shah JS
    J Assoc Physicians India; 1985 May; 33(5):339-43. PubMed ID: 3900029
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical cardiac electrophysiological assessment of indoramin.
    Butrous GS; Camm AJ
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S137-43. PubMed ID: 2423787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute effects of intravenous indoramin on the hemodynamic adaptation at rest and during exercise in chronic congestive heart failure.
    De Kock MR; Detry JM
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S107-11. PubMed ID: 2423782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in the effects of alpha-1 adrenergic blockade with prazosin and indoramin on coronary blood flow during exercise.
    Bache RJ; Homans DC; Schwartz JS; Dai XZ
    J Pharmacol Exp Ther; 1988 Apr; 245(1):232-7. PubMed ID: 2896237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of the hypotensive action of prazosin.
    Oates HF; Graham RM; Stokes GS
    Arch Int Pharmacodyn Ther; 1977 May; 227(1):41-8. PubMed ID: 901072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance of tonic vasomotor activity by alpha and beta adrenergic mechanisms in medullary cardiovascular centers.
    Ito A; Schanberg SM
    J Pharmacol Exp Ther; 1974 May; 189(2):392-404. PubMed ID: 4829221
    [No Abstract]   [Full Text] [Related]  

  • 40. Cardioregulatory properties of indoramin in the rat.
    Algate DR; Rashid S; Waterfall JF
    J Pharm Pharmacol; 1981 Apr; 33(4):236-9. PubMed ID: 6115907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.